Evogene Q4 Earnings Call Highlights

Evogene (NASDAQ: EVGN) executives used the company's fourth-quarter and full-year 2025 results call to outline a strategic transformation that narrowed its technology and market focus, while the finance team detailed the impact of cost reductions, discontinued operations, and several subsidiary-level changes. Strategy shift centers on ChemPass AI and two end markets President and CEO Ofer Haviv